Irinotecan Accord

Irinotecan, the active ingredient in Irinotecan Accord, is a topoisomerase I inhibitor presented as an intravenous formulation for use in cancer therapy. It is employed primarily to treat colorectal cancer in adult patients, acting to disrupt DNA replication in malignant cells.

GNH USA supplies Irinotecan Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global oncology treatment needs. Clients benefit from reliable logistics and dedicated technical support throughout the procurement process.

Irinotecan is a topoisomerase I inhibitor used in the management of colorectal cancer.

Metastatic colorectal cancer: improves overall survival as part of combination chemotherapy. Adjuvant colorectal cancer: reduces disease recurrence after surgical resection. First‑line colorectal cancer: administered with fluorouracil and leucovorin in the FOLFIRI regimen.

Irinotecan may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Diarrhea: may be severe and require supportive care. - Nausea and vomiting: often managed with antiemetics. - Fatigue: generalized tiredness during treatment. - Alopecia: hair loss that is usually reversible. - Anemia: decreased red blood cell levels.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent care. - Intestinal perforation: severe abdominal emergency. - Severe allergic reactions: anaphylaxis or hypersensitivity. - Hepatic toxicity: elevated liver enzymes or jaundice. - Cardiac events: rare arrhythmias or ischemia.

When using Irinotecan, several precautions should be observed to minimize risks.

Monitor blood counts: regular CBC to detect neutropenia. Assess liver function: evaluate hepatic enzymes before and during therapy. Maintain hydration: adequate fluids reduce severity of diarrhea. Avoid use in pregnancy: only if benefits outweigh potential fetal risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan can interact with other medicines, affecting its safety and efficacy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase SN‑38 exposure. - UGT1A1 inhibitors (e.g., atazanavir): raise risk of severe neutropenia. - Concurrent myelosuppressive agents: amplify bone‑marrow toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Anticoagulants (e.g., warfarin): monitor coagulation parameters. - Diuretics: watch for electrolyte imbalances during diarrhea.